Loading
Twenty melanoma patients took stool capsules from healthy donors before starting immunotherapy. Thirteen responded, more than usually expected, and the transplant was safe.
Phase 1 safety trial of healthy-donor capsule FMT (about 80-100 capsules, single dose) combined with first-line anti-PD-1. Objective response rate was 65% (13 of 20), including 4 complete responses, versus a historical 40-45% for anti-PD-1 monotherapy; responders had greater engraftment of donor strains and increased abundance of immunogenic taxa. Grade 3 immune-related adverse events occurred in 5 patients, none attributed to FMT. The trial moved FMT from a salvage strategy to a potential first-line adjunct and led to the Canadian Cancer Trials Group randomised phase 2 (LND101, NCT06623461). The historical comparison is not a control and the sample is small.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Take faecal transplant plus immunotherapy to a definitive trial, Microbiome modulation to unlock immunotherapy, Gut microbiome diversity and composition, Faecal microbiota transplantation for PD-1 non-responders.
Shares Microbiome modulation to unlock immunotherapy, Gut microbiome diversity and composition, Microbiome-tumour interactions, Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment.
Shares Microbiome modulation to unlock immunotherapy, Gut microbiome diversity and composition, Faecal microbiota transplantation for PD-1 non-responders, Microbiome-tumour interactions.
Shares Gut microbiome diversity and composition, No one can predict who responds to immunotherapy, Nivolumab, Melanoma.
Shares No one can predict who responds to immunotherapy, Nivolumab, Melanoma, Pembrolizumab.
Shares Take faecal transplant plus immunotherapy to a definitive trial, Faecal microbiota transplantation for PD-1 non-responders, Immune checkpoint inhibitors.
Shares Faecal microbiota transplantation for PD-1 non-responders, Microbiome-tumour interactions.
Shares No one can predict who responds to immunotherapy, Melanoma, Pembrolizumab, Immune checkpoint inhibitors.